When the deal closes, Endo will become a wholly owned subsidiary of Mallinckrodt. The combined company will take on a yet-to-be-determined name and is expected to trade on the New ...

Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S. footprint. The companies said Thursday they reached a definitive ...

Endo Inc. said Tuesday it has entered into an agreement to divest its international pharmaceuticals business to Knight Therapeutics in a deal valued at up to $99 million. The proposed sale ...